Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $18

Benzinga · 2d ago
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $23 to $18.